CMRX Stock Overview
A biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases.
Snowflake Score | |
---|---|
Valuation | 4/6 |
Future Growth | 2/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Chimerix, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$0.87 |
52 Week High | US$1.30 |
52 Week Low | US$0.75 |
Beta | 1.11 |
11 Month Change | 5.45% |
3 Month Change | -7.06% |
1 Year Change | -21.20% |
33 Year Change | -87.58% |
5 Year Change | -58.92% |
Change since IPO | -95.39% |
Recent News & Updates
Recent updates
We're Keeping An Eye On Chimerix's (NASDAQ:CMRX) Cash Burn Rate
Jul 16Chimerix: Advancement For Rare Brain Cancer Drug Targeting Specific Mutation
Aug 23Here's Why We're Watching Chimerix's (NASDAQ:CMRX) Cash Burn Situation
Jul 20Chimerix: Down But Not Out
Jun 06Chimerix: Searching For Clarity
Jan 05Does Chimerix (NASDAQ:CMRX) Have A Healthy Balance Sheet?
Dec 24Is Chimerix (NASDAQ:CMRX) A Risky Investment?
Sep 16Does Chimerix (NASDAQ:CMRX) Have A Healthy Balance Sheet?
Jun 08Chimerix gets FDA approval for TEMBEXA for the treatment of smallpox
Jun 04Chimerix, Inc. (NASDAQ:CMRX): Are Analysts Optimistic?
May 13Chimerix Investor Presentation - Slideshow
May 08Chimerix expands oncology program with acquisition of Oncoceutics, shares up 10%
Jan 08Who Has Been Buying Chimerix, Inc. (NASDAQ:CMRX) Shares?
Jan 01Chimerix rises 9.1% premarket after FDA accepts NDA for smallpox countermeasure
Dec 07Chimerix (NASDAQ:CMRX) Is In A Good Position To Deliver On Growth Plans
Dec 05Chimerix, Inc. 2020 Q3 - Results - Earnings Call Presentation
Nov 08Shareholder Returns
CMRX | US Biotechs | US Market | |
---|---|---|---|
7D | -11.8% | -2.1% | -1.9% |
1Y | -21.2% | 13.4% | 20.9% |
Return vs Industry: CMRX underperformed the US Biotechs industry which returned 14% over the past year.
Return vs Market: CMRX underperformed the US Market which returned 22.7% over the past year.
Price Volatility
CMRX volatility | |
---|---|
CMRX Average Weekly Movement | 9.0% |
Biotechs Industry Average Movement | 10.5% |
Market Average Movement | 6.3% |
10% most volatile stocks in US Market | 15.0% |
10% least volatile stocks in US Market | 3.1% |
Stable Share Price: CMRX has not had significant price volatility in the past 3 months.
Volatility Over Time: CMRX's weekly volatility (9%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2000 | 72 | Mike Andriole | www.chimerix.com |
Chimerix, Inc., a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors. The company also develops ONC212, an imipridone agonist of the orphan G protein-coupled receptors (GPCR) tumor suppressor GPR132, as well as ClpP for oncology indications; and CMX521, a nucleoside analog antiviral drug candidate for the treatment of SARS-CoV-2.
Chimerix, Inc. Fundamentals Summary
CMRX fundamental statistics | |
---|---|
Market cap | US$83.55m |
Earnings (TTM) | -US$84.70m |
Revenue (TTM) | US$144.00k |
539.6x
P/S Ratio-0.9x
P/E RatioIs CMRX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
CMRX income statement (TTM) | |
---|---|
Revenue | US$144.00k |
Cost of Revenue | US$70.31m |
Gross Profit | -US$70.17m |
Other Expenses | US$14.53m |
Earnings | -US$84.70m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -0.94 |
Gross Margin | -48,727.78% |
Net Profit Margin | -58,820.14% |
Debt/Equity Ratio | 0% |
How did CMRX perform over the long term?
See historical performance and comparison